Virus-like particles and process for preparing same
AssigneeFolia Biotech Inc.
InventorsDenis Leclerc, Pierre Savard
Life of this patent
Estimating the term…
Abstract
An in vitro process of preparing virus-like particles (VLPs) from recombinant papaya mosaic virus coat protein and ssRNA, which allows for large scale production of VLPs in high yields, is provided. Also provided are VLPs comprising ssRNA prepared by the in vitro process. The VLPs can be used as adjuvants and when fused to an antigen, as vaccines. The use of the VLPs for stimulation of the innate immune response is also provided.
Claims44
An in vitro process for preparing virus-like particles (VLPs) comprising the steps of:
- a) combining recombinant potexvirus coat protein and ssRNA at a protein:RNA ratio of between about 1:1 and 50:1 by weight, at a pH between about 6.0 and about 9.0, and a temperature between about 2° C. and about 37° C., for a time sufficient to allow assembly of VLPs;
- b) treating the VLPs with nuclease to remove any RNA protruding from the particles, and
- c) separating the VLPs from other process components.
A papaya mosaic virus (PapMV) virus-like particle (VLP) comprising recombinant PapMV coat protein and ssRNA, wherein the ssRNA is between about 50 nucleotides and about 5000 nucleotides in length and comprises a sequence corresponding to the nucleic acid sequence as set forth in SEQ ID NO:5 or 6, or a fragment thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An in vitro process for preparing papaya mosaic virus (PapMV) virus-like particles (VLPs) comprising the steps of:
- a) combining recombinant PapMV coat protein and ssRNA at a protein:RNA ratio of between about 5:1 and 40:1 by weight, in a buffered solution at a pH between about 6.5 and about 8.5, and a temperature between about 22° C. and about 37° C., for a time sufficient to allow assembly of VLPs, wherein the recombinant PapMV is predominantly in the form of low molecular weight species of less than 20-mers;
- b) treating the VLPs with nuclease to remove any RNA protruding from the particles, and
- c) separating the VLPs from other process components.
Dependencies are inferred from the claim text.